Article

First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma

2023-09-21

Abstract excerpt

<title>Abstract</title> <p>Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade B-cell lymphoma of the bone marrow. Despite a cumulative risk of progression, there is no approved therapy for patients in the asymptomatic phase. We conducted a first-in-human clinical trial of a novel therapeutic DNA idiotype neoantigen vaccine in nine patients with asymptomatic LPL. Treatment was well tolerated with no dose l...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c93eaf1f-55c9-5c18-99b8-9c12f1c44960
DOI: 10.21203/rs.3.rs-3315017/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphomaDOI 10.21203/rs.3.rs-3315017/v1Read

Systemic neoantigen-specific T cells reveal central determinants of PD-(L)1 blockade efficacySemantic proximity Read

Polyclonal expansion of functional tumor-reactive lymphocyte infiltrating glioblastoma for personalized cell therapySemantic proximity Read

Systems-level immunomonitoring in children with solid tumors to enable precision medicineSemantic proximity Read

Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular LymphomaSemantic proximity Read

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma.Semantic proximity Read

Neoantigens and Stochastic Fluctuations Regulate T Cell Proliferation in Primary and Metastatic Malignant Brain TumorsSemantic proximity Read

Cross-competition shapes CD8+ T cell hierarchies and fate after cancer neoantigen RNA vaccinationSemantic proximity Read

In vivo vaccination with cell line-derived whole tumor lysates – neoantigen quality, not quantity mattersSemantic proximity Read

Vaccination rescues dysfunctional T cell therapy by amplifying rare stem-like antitumor CD8⁺ T cellsSemantic proximity Read

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.Semantic proximity Read

Personalized Neoantigen Vaccines Synergize with Immune Checkpoint Therapy and CD8-Targeted Cytokines to Control B-Cell LymphomaSemantic proximity Read

Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell TherapySemantic proximity Read